Dr. Reddy's Laboratories announces the launch of Valsartan Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Diovan® brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Dr. Reddy's Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4571.20 as compared to the previous close of Rs. 4528.50. The total number of shares traded during the day was 23566 in over 1915 trades.

The stock hit an intraday high of Rs. 4589.00 and intraday low of 4511.10. The net turnover during the day was Rs. 107224635.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY Pharmaceuticals ValsartanTablets USFDA